HALO: Financial results

Item 2.02 Results of Operations and Financial Condition. On May 11, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release dated May 11, 2026 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc (Registrant) Dated: May 11, 2026 By: /s/ David Ramsay David Ramsay Interim Chief Financial Officer